AzTrials
AzTrials

Osteoarthritis, KneePhase 1/2NCT05288725

Mesenchymal Stem Cell Therapy for Knee Osteoarthritis

A Phase 1/2 study testing Bone Marrow Derived MSCs, Corticosteroid and Bone Marrow Aspirate in people with Osteoarthritis, Knee, run by Next Generation Regenerative Medicine LLC at 3 sites in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The study is a multicentered, randomized, double-blinded, placebo-controlled study conducted on the unilateral knee of 120 patients. The study compares the effectiveness of an injection of a mesenchymal stem cell preparation from autologous bone marrow aspirate (BMA) to a corticosteroid control for knee… Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Osteoarthritis, Knee
What is being tested?
Bone Marrow Derived MSCs, Corticosteroid and Bone Marrow Aspirate
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
3 sitesUnited States
Study dates
Aug 2022to Dec 2024
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • The subject must be willing and able to provide written informed consent.
  • Healthy, non-smoking, males and females.
  • Negative Pregnancy test.
  • Body weight > 45 kg and Body Mass Index (BMI) between 18 and 40 kg/m2 (i.e., subjects with a BMI >40 and <18 will be excluded).
  • No clinically significant abnormal findings on blood pressure, heart rate, physical examination, clinical laboratory tests, or Electrocardiogram (ECG). See details below:
  • Heart Rate (HR) >60 and <100 bpm
Show all 26Show fewer
  • Systolic Blood Pressure (BP) >90 and <170 mmHg
  • Diastolic BP >60 and <80 mmHg
  • Pulse oximetry ≥95% at room air
  • Temperature: normal
  • Laboratory measures within normal range
  • Liver enzymes <2 x Upper Limit of Normal (ULN)
  • Normal bilirubin
  • Normal Pain Threshold (PT) / International Normalized Ratio (INR)
  • Estimated Glomerular Filtration Rate (eGFR) >60 ml/min
  • Normal ECG.
  • Individuals 18 to 80 years old that have knee Osteoarthritis.
  • X-rays that demonstrate OA with the Kellgren-Lawrence grading scale of 2, 3 or 4 in at least one compartment of the knee either or both knees. Only subjects that have a single symptomatic knee will be enrolled.
  • No significant Medial Collateral Ligament (MCL) or Lateral Collateral Ligament (LCL) tear or laxity. (A significant LCL and MCL laxity or tear would be determined on clinical exam if there is no endpoint on valgus or Varus stress physical exam. Upon review of the MRI, NGRM will only treat subjects with no grade 2 or grade 3 ligamentous sprains [LCL, MCL, Anterior Cruciate Ligament (ACL), Posterior Cruciate Ligament (PCL)]. Next Generation Regenerative Medicine (NGRM) will treat subjects with degenerative meniscal changes in tears but no acute or large bucket handle tears.)
  • No significant meniscal tear. (i.e. bucket handle) (A positive McMurrays test on clinical exam indicates a significant meniscal tear. The subjects will also be getting a baseline MRI that will help delineate any further ligament injuries that may disqualify a subject.)
  • Subjects who have had the benefit of standard of care (SOC) treatment (activity modification, weight loss, physical therapy, anti-inflammatory medications, or injection therapy) before receiving experimental therapy. However, subjects cannot have had the benefit of standard of care treatment at less than 3 months before receiving experimental therapy. Enroll subjects who have demonstrated failure or are intolerant to SOC treatment. The time frame prior to screening when failure of conservative treatment would have occurred will be one year of symptoms and failure of conservative treatment which includes physical therapy, nonsteroidal anti-inflammatory medicine, cortizone injections, or hyaluronic acid injections.
  • Treatment failure is indicated by Subjects having symptoms of knee pain, swelling, and trouble with activities for at least 4 to 6 weeks. Subjects would only be enrolled if they fail conservative treatment. Usually physical therapy is administered initially for 6 weeks along with an NSAID medication. If that fails, which means that pain and swelling and disability continue, then injection therapy with corticosteroid or hyaluronic acid (HA) is given. Usually the injection is followed up in 6 to 8 weeks post-injection. If that fails, then Orthobiologics will be discussed (at about 4 to 6 months after treatment).
  • The subject must fail at least two conservative treatments, which could include physical therapy and NSAIDs, or physical therapy and injections, or NSAIDs and injections.
  • Subjects must have WOMAC and VAS scores of ≥30 and ≥4, respectively at least 2 weeks prior to enrollment.
  • Male and female subjects of reproductive potential must agree to refrain from sexual activity or use effective birth control for a duration of one week before and three months after initiation of treatment with either active treatment modality.
  • Subjects with basal cell, in situ carcinoma, or remote history (i.e., > 3 years ago) history of low-grade cancers (e.g., breast) that were effectively treated may be included.

Who cannot join

  • Tibia on femur subluxation greater than 1mm. Varus or valgus number greater than 9°.
  • Intra-articular injection to affected knee within 6 weeks of BMA injection
  • Subjects who have had recent administration of intra- articular injection (e.g. corticosteroid, viscosupplement, platelet-rich plasma (PRP), or any other stem cell therapy) within the last 3 months prior to the experimental therapy.
  • Subjects who have had recent systemic (oral (PO), intravenous (IV) and/or intramuscular (IM) within 6 weeks of treatment) administration of corticosteroids; including subjects who are likely to need or who are currently on systemic steroids (e.g., asthma)
  • Subjects with a BMI of >40 and <18 will be excluded.
  • Fever, active infection and ongoing infectious diseases, including HIV and hepatitis
Show all 22Show fewer
  • Clinically significant diabetes (HGB A1C >7%), cardiovascular (stable cardiovascular (CV) disease as indicated by treating cardiologist within 30 days of enrollment and/or an ejection fraction of <55%), hepatic (Pugh score of Class A or less than 6), or renal disease (Stage 1 or more severe).
  • Malignancy of the blood such as leukemia or lymphoma or those malignancies which are not > 5 years post treatment including prostate cancer, breast cancer, thyroid cancer, kidney cancer or lung cancer. Subjects with an active malignancy, or subjects with a history of any malignancy (e.g., including in situ, basal cell, etc.) will be excluded.
  • Use of anti-rheumatic medications, including methotrexate and other anti-metabolites.
  • Patients that are chronically taking Plavix, Coumadin and other anticoagulants for stroke/myocardial infarction/thromboembolic phenomena prevention, and/or Pradaxa, Xarelto, Mylanta, Fish Oil, Elmiron, Cipro, Levaquin, Quinolones, Ibuprofen, aspirin, Naproxen, CBD oil, Turmeric, or Meloxicam.
  • Current chemo or radiation therapy
  • Current drug or alcohol use disorder
  • Subjects with h/o noncompliance or serious emotional disabilities, and/or any thought disorder, etc. will be excluded
  • History of severe anemia or bleeding disorders (infectious arthritis, hemophilic arthropathy, Charcot's knee) (Anemia for the study is defined as Hgb 12 g/dL.)
  • History of severe metabolic bone disease (osteoporosis, osteomalacia, rickets, osteitis fibrosa cystica, Paget's disease of bone) (Metabolic bone disease is osteoporosis diagnosed by DEXA scan, Leukemia, aplastic anemia or bone Metastasis.)
  • Pregnant or currently breast-feeding. Males and females of reproductive potential will refrain from sexual activity or use effective birth control for up to 90 days following product administration.
  • History of systemic chondrocalcinosis.
  • Vitamin D levels < 30 ng/mL.
  • Subjects who are unwilling to forgo pain medication during and for a 2 weeks before clinical assessments will be excluded to decrease the potential for confounding of the efficacy assessments.
  • Subjects with claudication and vascular disorders (such as varicose veins or peripheral arterial disease), neurological disorders or other disabilities aside from osteoarthritis that may affect ambulation.
  • Physical Exam findings include severe peripheral vascular disease, deep vain thrombosis (DVT), heart murmur, clubbing, open wounds, and other specific knee findings including significant varus or valgus deformity or subluxation of the femoral - tibial joint space, patellar tracking issues, trendelenburg gait or extremity weakness or significant peripheral neuropathy.
  • Subjects may not have popliteal Baker's cyst(s).

Trial locations and contacts

3 sites in 1 country.

United States3 sites

  • Bluetail Medical Group

    Chesterfield, Missouri, 63005

    Phebe Moore

    David M Crane, M.D.

  • Albano Clinic

    Salt Lake City, Utah, 84121

    Lauren Dunn

    Joseph J Albano, M.D.

  • Scarpone Sports Regenerative

    Steubenville, Ohio, 43952

    Dina Scarpone, RN

    Michael A Scarpone, D.O.

Other trials in United States

About this study

Official title: A Study to Evaluate the Safety, and Efficacy of Minimally Manipulated Autologous Bone Marrow Aspirate to Treat Knee Osteoarthritis in Patients

The study is a multicentered, randomized, double-blinded, placebo-controlled study conducted on the unilateral knee of 120 patients. The study compares the effectiveness of an injection of a mesenchymal stem cell preparation from autologous bone marrow aspirate (BMA) to a corticosteroid control for knee osteoarthritis. WOMAC, VAS pain scores, and MRI will be used for assessment. The study will be conducted at 3 sites in the United States.

Read the detailed description

Osteoarthritis (OA) is the most common form of arthritis in the knee that affects millions of adults throughout the world and is the leading cause of disability. It is a degenerative type of arthritis that occurs most often in patients, as the cartilage in the knee joint gradually wears away. As the cartilage wears away, it becomes frayed and rough, and the protective space between the bones decreases. This can result in bone rubbing on bone and produce painful bone spurs. The patient experiences pain that worsens over time.

Although current surgical therapeutic procedures to cartilage repair are clinically useful, they cannot restore a normal articular surface, and in many cases, resulted in the growth of inferior quality fibrocartilage. Therefore, techniques and practices have been developed to collect minimally manipulated bone marrow aspirate (BMA), that contains Bone Marrow Derived Mesenchymal Stem Cells (BMDMSCs) and other endogenous acellular components, from knee OA patients for autologous transplantation in the treatment of their knee OA.

Participants will be randomized to study arms to receive a BMA injection to the intra-articular knee, subchondral knee, both intra-articular and subchondral knee, or to receive a corticosteroid injection to the knee. A corticosteroid injection is currently the standard of care for osteoarthritis patients having knee pain. All participants will undergo a procedure. Participants will be blinded as to whether they receive a BMA injection or a corticosteroid injection.

Being tested
Bone Marrow Derived MSCs, Corticosteroid, Bone Marrow Aspirate
Keywords
Osteoarthritis, Knee Osteoarthritis, Knee Pain, Bone Marrow Aspirate, Mesenchymal Stem Cells, Cell Therapy, Corticosteroid, Regenerative Medicine, Functional Improvement
Medical subject headings
Osteoarthritis, Knee, Osteoarthritis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bone Marrow Derived MSCsBiological

    Also called Bone Marrow Aspirate, Marrow Cellutions

    Autologous bone marrow aspirate (BMA) is an orthobiologic injection used in knee osteoarthritis therapy. Bone marrow aspirate is harvested from the posterior superior iliac crest (PSIS) of the spine using the Marrow Cellutions kit. BMA will be injected into the knee using ultrasound guidance.

  • CorticosteroidDrug

    Also called Kenalog

    The corticosteroid is prepared in a 10 ml syringe by combining 1-2 mL Kenalog [40 mg/dL], 6-8 mL sterile normal saline, 3-4 mL Ropivicaine 1%.

  • Bone Marrow AspirateDevice

    The Marrow Cellutions kit is an FDA approved device for harvesting bone marrow aspirate.

Study groups in NCT05288725
Study groupRoleWhat they receive
Intra-articular injection with Bone Marrow Derived Mesenchymal Stem Cells (MSCs)ExperimentalParticipants will undergo a bone marrow aspirate procedure. Participants will receive a single intra-articular injection of NGRM-001 on treatment day.
Receives: Biological: Bone Marrow Derived MSCs; Device: Bone Marrow Aspirate
Subchondral injection with Bone Marrow Derived MSCsExperimentalParticipants will undergo a bone marrow aspirate procedure. Participants will receive a single subchondral injection of NGRM-001 on treatment day.
Receives: Biological: Bone Marrow Derived MSCs; Device: Bone Marrow Aspirate
Combined Intra-articular and Subchondral injection with Bone Marrow Derived MSCsExperimentalParticipants will undergo a bone marrow aspirate procedure. Participants will receive a single combined intra-articular and subchondral injection of NGRM-001 on treatment day.
Receives: Biological: Bone Marrow Derived MSCs; Device: Bone Marrow Aspirate
Corticosteroid injectionActive comparatorSubjects in the corticosteroid group will undergo a mock bone marrow aspirate procedure. Participants will receive a single intra-articular injection of corticosteroid on treatment day.
Receives: Drug: Corticosteroid; Device: Bone Marrow Aspirate

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from Baseline Western Ontario McMaster University Osteoarthritis Index (WOMAC) at 3 months

    The Western Ontario and McMaster Universities Osteoarthritis Index is a widely used, proprietary set of standardized questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee and hip, including pain, stiffness, and physical functioning of the joints. The test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4).

    The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. A sum of the scores for all three subscales gives a total WOMAC score. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations. The minimum clinically important difference (MCID) for this parameter is ≥ 10.

    Measured: 3 months

  2. Change from Baseline Western Ontario McMaster University Osteoarthritis Index (WOMAC) at 6 months

    The Western Ontario and McMaster Universities Osteoarthritis Index is a widely used, proprietary set of standardized questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee and hip, including pain, stiffness, and physical functioning of the joints. The test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4).

    The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. A sum of the scores for all three subscales gives a total WOMAC score. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations. The minimum clinically important difference (MCID) for this parameter is ≥ 10.

    Measured: 6 months

  3. Change from Baseline Western Ontario McMaster University Osteoarthritis Index (WOMAC) at 12 months

    The Western Ontario and McMaster Universities Osteoarthritis Index is a widely used, proprietary set of standardized questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee and hip, including pain, stiffness, and physical functioning of the joints. The test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4).

    The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. A sum of the scores for all three subscales gives a total WOMAC score. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations. The minimum clinically important difference (MCID) for this parameter is ≥ 10.

    Measured: 12 months

  4. Change from Baseline Visual Analog Score (VAS) at 3 months

    The pain VAS is a unidimensional scale of pain that is widely used and well validated in diverse groups of adult patients. The horizontal scale will be anchored by "no pain" (0) with "worst imaginable pain" (10) being at the opposite extreme. The minimum clinically important difference (MCID) for this measure is VAS ≥ 2

    Measured: 3 months

  5. Change from Baseline Visual Analog Score (VAS) at 6 months

    The pain VAS is a unidimensional scale of pain that is widely used and well validated in diverse groups of adult patients. The horizontal scale will be anchored by "no pain" (0) with "worst imaginable pain" (10) being at the opposite extreme. The minimum clinically important difference (MCID) for this measure is VAS ≥ 2

    Measured: 6 months

  6. Change from Baseline Visual Analog Score (VAS) at 12 months

    The pain VAS is a unidimensional scale of pain that is widely used and well validated in diverse groups of adult patients. The horizontal scale will be anchored by "no pain" (0) with "worst imaginable pain" (10) being at the opposite extreme. The minimum clinically important difference (MCID) for this measure is VAS ≥ 2

    Measured: 12 months

  7. Magnetic Resonance Imaging (MRI) Evaluation

    Magnetic resonance imaging (MRI) is a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body in both health and disease. MRI scanners use strong magnetic fields, radio waves, and field gradients to generate images of the inside of the body.

    Measured: Baseline and 12 months

Secondary outcomes (12)

  1. Change from baseline measure of Fall Risk Functional Testing at 3 months

    Fall Risk Functional Testing

    Measured: 3 months

  2. Change from baseline measure of Fall Risk Functional Testing at 6 months

    Fall Risk Functional Testing

    Measured: 6 months

  3. Change from baseline measure of Fall Risk Functional Testing at 12 months

    Fall Risk Functional Testing

    Measured: 12 months

  4. Change from baseline measure of Frailty Functional Testing at 3 months

    Frailty Functional Testing

    Measured: 3 months

  5. Change from baseline measure of Frailty Functional Testing at 6 months

    Frailty Functional Testing

    Measured: 6 months

  6. Change from baseline measure of Frailty Functional Testing at 12 months

    Frailty Functional Testing

    Measured: 12 months

  7. Change from baseline measure of Joint Specific Range of Motion Functional Testing at 3 months.

    Joint Specific Range of Motion Functional Testing

    Measured: 3 months

  8. Change from baseline measure of Joint Specific Range of Motion Functional Testing at 6 months.

    Joint Specific Range of Motion Functional Testing

    Measured: 6 months

  9. Change from baseline measure of Joint Specific Range of Motion Functional Testing at 12 months.

    Joint Specific Range of Motion Functional Testing

    Measured: 12 months

  10. Change from baseline measure of Obesity Functional Testing at 3 months

    Obesity Functional Testing

    Measured: 3 months

  11. Change from baseline measure of Obesity Functional Testing at 6 months

    Obesity Functional Testing

    Measured: 6 months

  12. Change from baseline measure of Obesity Functional Testing at 12 months

    Obesity Functional Testing

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Mar 2022
  2. Study startAug 2022 (estimated)
  3. Primary completionJun 2024 (estimated)
  4. Study completionDec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05288725
Sponsor's protocol ID
NGRM-001
Status last verified
Feb 2022
First submitted
15 Feb 2022
Last updated
21 Mar 2022
Results posted
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
Individual data sharing
No: IPD Sharing Plan: Not Applicable

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing Bone Marrow Derived MSCs, Corticosteroid and Bone Marrow Aspirate in people with Osteoarthritis, Knee, run by Next Generation Regenerative Medicine LLC at 3 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 26 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 21 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from Baseline Western Ontario McMaster University Osteoarthritis Index (WOMAC) at 3 months (time frame: 3 months). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05288725.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Mar 2022.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in